Mesa Laboratories, Inc. (NASDAQ:MLAB) Director H Stuart Campbell sold 608 shares of the business’s stock in a transaction that occurred on Friday, August 11th. The shares were sold at an average price of $134.08, for a total value of $81,520.64. Following the transaction, the director now directly owns 45,368 shares in the company, valued at $6,082,941.44. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

H Stuart Campbell also recently made the following trade(s):

  • On Wednesday, August 9th, H Stuart Campbell sold 1,000 shares of Mesa Laboratories stock. The shares were sold at an average price of $137.61, for a total value of $137,610.00.
  • On Thursday, August 10th, H Stuart Campbell sold 1,000 shares of Mesa Laboratories stock. The shares were sold at an average price of $136.58, for a total value of $136,580.00.
  • On Friday, August 4th, H Stuart Campbell sold 1,000 shares of Mesa Laboratories stock. The shares were sold at an average price of $143.09, for a total value of $143,090.00.
  • On Thursday, August 3rd, H Stuart Campbell sold 2,000 shares of Mesa Laboratories stock. The shares were sold at an average price of $143.37, for a total value of $286,740.00.

Mesa Laboratories, Inc. (MLAB) traded down 1.43% during trading on Tuesday, hitting $131.93. The stock had a trading volume of 4,189 shares. Mesa Laboratories, Inc. has a 12 month low of $102.14 and a 12 month high of $169.80. The stock has a market cap of $495.79 million, a price-to-earnings ratio of 47.42 and a beta of 0.46. The stock has a 50 day moving average price of $143.67 and a 200-day moving average price of $136.35.

Mesa Laboratories (NASDAQ:MLAB) last released its quarterly earnings data on Monday, July 31st. The medical instruments supplier reported $0.39 EPS for the quarter, missing the consensus estimate of $0.56 by $0.17. Mesa Laboratories had a return on equity of 16.58% and a net margin of 11.31%. The firm had revenue of $22.67 million for the quarter, compared to analysts’ expectations of $22.90 million. On average, equities analysts predict that Mesa Laboratories, Inc. will post $2.72 EPS for the current year.

The business also recently declared a quarterly dividend, which will be paid on Friday, September 15th. Stockholders of record on Thursday, August 31st will be issued a $0.16 dividend. The ex-dividend date is Tuesday, August 29th. This represents a $0.64 dividend on an annualized basis and a dividend yield of 0.48%. Mesa Laboratories’s dividend payout ratio is presently 22.94%.

COPYRIGHT VIOLATION NOTICE: This piece was originally published by Watch List News and is owned by of Watch List News. If you are viewing this piece on another website, it was stolen and republished in violation of United States and international trademark and copyright law. The legal version of this piece can be accessed at https://www.watchlistnews.com/h-stuart-campbell-sells-608-shares-of-mesa-laboratories-inc-mlab-stock/1491462.html.

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Pembroke Management LTD bought a new position in shares of Mesa Laboratories during the second quarter worth about $8,283,000. Thomson Horstmann & Bryant Inc. increased its position in shares of Mesa Laboratories by 75.4% in the second quarter. Thomson Horstmann & Bryant Inc. now owns 72,362 shares of the medical instruments supplier’s stock worth $10,370,000 after buying an additional 31,107 shares in the last quarter. Royce & Associates LP increased its position in shares of Mesa Laboratories by 56.8% in the second quarter. Royce & Associates LP now owns 78,530 shares of the medical instruments supplier’s stock worth $11,254,000 after buying an additional 28,458 shares in the last quarter. Vanguard Group Inc. increased its position in shares of Mesa Laboratories by 10.1% in the second quarter. Vanguard Group Inc. now owns 145,161 shares of the medical instruments supplier’s stock worth $20,804,000 after buying an additional 13,263 shares in the last quarter. Finally, Martingale Asset Management L P bought a new position in shares of Mesa Laboratories during the second quarter worth about $1,161,000. Institutional investors and hedge funds own 67.11% of the company’s stock.

MLAB has been the topic of several research analyst reports. Zacks Investment Research raised Mesa Laboratories from a “hold” rating to a “buy” rating and set a $169.00 target price on the stock in a research note on Tuesday, May 23rd. TheStreet cut Mesa Laboratories from a “b” rating to a “c+” rating in a research note on Monday, July 31st. Finally, BidaskClub cut Mesa Laboratories from a “hold” rating to a “sell” rating in a research note on Monday, July 31st.

About Mesa Laboratories

Mesa Laboratories, Inc is focused primarily on quality control products and services. The Company operates through four segments: Instruments, Continuous Monitoring, Biological Indicators and Cold Chain. The Instruments Division designs, manufactures and markets quality control instruments and disposable products.

Insider Buying and Selling by Quarter for Mesa Laboratories (NASDAQ:MLAB)

Receive News & Ratings for Mesa Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesa Laboratories Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.